These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 25528312)

  • 41. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
    Min T; Davies GI; Rice S; Chess J; Stephens JW
    Diabetes Metab Syndr; 2018; 12(2):123-127. PubMed ID: 29239764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry.
    Bae EH; Lim SY; Cho KH; Choi JS; Kim CS; Park JW; Ma SK; Jeong MH; Kim SW
    Am J Kidney Dis; 2012 Jun; 59(6):795-802. PubMed ID: 22445708
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sitagliptin and the risk of hospitalization for heart failure: a population-based study.
    Wang KL; Liu CJ; Chao TF; Huang CM; Wu CH; Chen SJ; Yeh CM; Chen TJ; Lin SJ; Chiang CE
    Int J Cardiol; 2014 Nov; 177(1):86-90. PubMed ID: 25499347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic kidney disease and long-term outcomes of myocardial infarction.
    Nagashima M; Hagiwara N; Koyanagi R; Yamaguchi J; Takagi A; Kawada-Watanabe E; Shiga T; Ogawa H
    Int J Cardiol; 2013 Sep; 167(6):2490-5. PubMed ID: 22569317
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus.
    Zeng DK; Xiao Q; Li FQ; Tang YZ; Jia CL; Tang XW
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study.
    Tseng WC; Liu JS; Hung SC; Kuo KL; Chen YH; Tarng DC; Hsu CC
    Int J Cardiol; 2017 Jul; 238():72-78. PubMed ID: 28363684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study.
    Kim NH; Choi J; Kim NH; Choi KM; Baik SH; Lee J; Kim SG
    Diabetes Metab; 2018 Sep; 44(4):361-367. PubMed ID: 29752167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.
    Savarese G; Perrone-Filardi P; D'Amore C; Vitale C; Trimarco B; Pani L; Rosano GM
    Int J Cardiol; 2015 Feb; 181():239-44. PubMed ID: 25528528
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study.
    Toh S; Reichman ME; Graham DJ; Hampp C; Zhang R; Butler MG; Iyer A; Rucker M; Pimentel M; Hamilton J; Lendle S; Fireman BH;
    Diabetes Care; 2018 Jan; 41(1):39-48. PubMed ID: 29122893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of chronic kidney disease in early invasive versus early conservative revascularization strategies in non-ST-segment elevation acute coronary syndromes: a population-based study from NHIRD of Taiwan.
    Chu CY; Su HM; Hsu PC; Lee WH; Lin TH; Voon WC; Lai WT; Sheu SH
    Nephron Clin Pract; 2013; 124(1-2):38-46. PubMed ID: 24080763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients.
    Contini GA; Nicolini F; Fortuna D; Pacini D; Gabbieri D; Vignali L; Valgimigli M; Manari A; Zussa C; Guastaroba P; De Palma R; Grilli R; Gherli T
    Int J Cardiol; 2013 Sep; 168(2):1028-33. PubMed ID: 23164591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors.
    Cea Soriano L; Johansson S; Stefansson B; Rodríguez LA
    Cardiovasc Diabetol; 2015 Apr; 14():38. PubMed ID: 25909295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34⁺CXCR4⁺ cells in patients with type 2 diabetes.
    Aso Y; Jojima T; Iijima T; Suzuki K; Terasawa T; Fukushima M; Momobayashi A; Hara K; Takebayashi K; Kasai K; Inukai T
    Endocrine; 2015 Dec; 50(3):659-64. PubMed ID: 26209038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study.
    Tanaka A; Yoshida H; Nanasato M; Oyama JI; Ishizu T; Ajioka M; Ishiki R; Saito M; Shibata Y; Kaku K; Maemura K; Higashi Y; Inoue T; Murohara T; Node K
    Int J Cardiol; 2018 Nov; 271():331-335. PubMed ID: 29803341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review.
    Yang CT; Peng ZY; Chen YC; Ou HT; Kuo S
    Front Endocrinol (Lausanne); 2022; 13():836365. PubMed ID: 35330915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Acute and Chronic Kidney Disease on Heart Failure Hospitalizations After Acute Myocardial Infarction.
    Yandrapalli S; Christy J; Malik A; Wats K; Harikrishnan P; Aronow W; Frishman W
    Am J Cardiol; 2022 Feb; 165():1-11. PubMed ID: 34893301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.